A phase II Randomized, Double Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination with Transarterial Chemoembolization (TACE) Performed with DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carinoma (HCC) [BAY 43-9006 / 12918]
ID Number 09-0693
Principal Investigator(s)Josep Llovet
Department(s) or Division(s)
Liver Diseases
Description
The purpose of this study is to see if the study drug Sorafenib, in combination with transarterial chemoembolization (TACE) performed with DC beads and doxorubicin (anti-cancer medication), will slow down tumor progression (advancement of your disease) and result in increased survival in patients with unresectable (can’t operate on) hepatocellular carcinoma.
Contact Information
Tanisha Brown
(212) 241-4028
tanisha.brown@mssm.edu
Recruiting Patients: Yes